Lannett Company, part of Aurobindo Pharma, has launched generic Advair Diskus in the US, making it the first complex inhalation product from Aurobindo to be marketed there. This market is worth approximately $908 million. Moreover, Cipla’s US branch has also obtained FDA approval for the same product, setting the stage for an exciting competition in respiratory treatments.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.